Ophthalmology

Ophthalmic Consultants of Long Island Inject Patient With JETREA

Daniel Kiernan, MD, of Ophthalmic Consultants of Long Island injected a patient suffering from vitreo-macular adhesion with JETREA, a dilution of ocriplasmin that is the first FDA approved drug to treat VMA, according to a report by the Times Union.

Carrie Pallardy

Tuesday, March 5th, 2013

This procedure was the first injection of the drug on Long Island.

JETREA, approved by the FDA in 2012, will be available at other Ophthalmic Consultants of Long Island locations.

More Articles on Ophthalmology:
Dr. Ryan Walsh Joins Medical College of Wisconsin
Miller School of Medicine, International Team Discover Seven Genes Linked to Macular Degeneration
Report Estimates Optical Imaging Market Worth $1.9B by 2018

Next Up in Ophthalmology

Massachusetts ophthalmology practice suffers data incident

Andover (Mass.) Eye Associates experienced a data security incident that impacted about 1,600 patients, according to a Jan. 12 report…

By: Cameron Cortigiano
Yesterday
Maryland ophthalmology practices merge, open joint facility

Maryland Vision Institute and Busack Eye Center have opened a shared practice in Frederick, Md. The two practices will begin…

By: Cameron Cortigiano
Friday, January 9th, 2026
3 Oklahoma ophthalmology practices acquired

Orlando, Fla.-based Ascend Vision Partners entered the Oklahoma market with the acquisition of three practices. according to a Jan. 7…

By: Patsy Newitt
Thursday, January 8th, 2026

Comments are closed.

From retrospective to real time: Transforming CMS Star Rating and Leapfrog objectives into bedside action

Next Up in Ophthalmology

Massachusetts ophthalmology practice suffers data incident

Maryland ophthalmology practices merge, open joint facility

3 Oklahoma ophthalmology practices acquired

Join the 40,000+ ASC leaders who start their day with Becker's